Cargando…

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy

BACKGROUND: Neoadjuvant endocrine therapy (NAE) has been employed to improve surgical outcomes for hormone receptor-positive breast cancers in postmenopausal women. Endocrine responsiveness is estimated by expressions of hormone receptors, but its heterogeneity has been recognized. Autophagy is an e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Takayuki, Saji, Shigehira, Sugimoto, Masahiro, Masuda, Norikazu, Kuroi, Katsumasa, Sato, Nobuaki, Takei, Hiroyuki, Yamamoto, Yutaka, Ohno, Shinji, Yamashita, Hiroko, Hisamatsu, Kazufumi, Aogi, Kenjiro, Iwata, Hiroji, Imoto, Shigeru, Sasano, Hironobu, Toi, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794811/ https://www.ncbi.nlm.nih.gov/pubmed/26984766 http://dx.doi.org/10.1186/s12885-016-2270-9

Ejemplares similares

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
por: Kuroi, Katsumasa, et al.
Publicado: (2014)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer
por: Inoue, Kenichi, et al.
Publicado: (2015)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

An overview of the Japan Breast Cancer Research Group (JBCRG) activities
por: Ohno, Shinji, et al.
Publicado: (2013)

Pharmacogenomic–pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer
por: Ishiguro, Hiroshi, et al.
Publicado: (2019)

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
por: Masuda, Norikazu, et al.
Publicado: (2021)

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
por: Ueno, Takayuki, et al.
Publicado: (2022)

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
por: Kawaguchi, Hidetoshi, et al.
Publicado: (2019)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01
por: Yamashiro, Hiroyasu, et al.
Publicado: (2020)

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
por: Watanabe, Toru, et al.
Publicado: (2017)

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
por: Masuyama, Misato, et al.
Publicado: (2023)

Impact of body mass index on breast cancer in accordance with the life-stage of women
por: Suzuki, Reiko, et al.
Publicado: (2012)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model
por: Takada, Masahiro, et al.
Publicado: (2012)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2022)

Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial
por: Tsuda, Moe, et al.
Publicado: (2020)

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network
por: Kiso, Marina, et al.
Publicado: (2018)

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
por: Masuda, Norikazu, et al.
Publicado: (2018)

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
por: Masuda, Norikazu, et al.
Publicado: (2020)

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol
por: Saji, Shigehira, et al.
Publicado: (1999)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
por: Iwata, Hiroji, et al.
Publicado: (2013)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2020)

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer
por: Uehiro, Natsue, et al.
Publicado: (2016)

Role of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma
por: Suzuki, Akio, et al.
Publicado: (1998)

Correction to: Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
por: Tsuda, Hitoshi, et al.
Publicado: (2022)

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial
por: Tsuda, Hitoshi, et al.
Publicado: (2022)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4f459pmkvmc5bds0ji6vvedlhn